|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0005773,
umls-concept:C0016360,
umls-concept:C0023413,
umls-concept:C0036525,
umls-concept:C0043474,
umls-concept:C0178602,
umls-concept:C0205100,
umls-concept:C0205195,
umls-concept:C0205210,
umls-concept:C0332120,
umls-concept:C0348016,
umls-concept:C0441655,
umls-concept:C0521447,
umls-concept:C0750502,
umls-concept:C0806909,
umls-concept:C1511698,
umls-concept:C1516213,
umls-concept:C1522484,
umls-concept:C1527249,
umls-concept:C1627358,
umls-concept:C2349975
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
1997-9-22
|
|
pubmed:abstractText |
Experimental studies have demonstrated that 5-fluorouracil (5-FU) enhances zidovudine (AZT)-induced DNA strand breaks and cytotoxicity. Phase I studies have demonstrated that the maximum tolerable dose (MTD) of AZT is 8000 mg/sqm when administered i.v. over two hours after weekly 5-FU + l-leucovorin (LV), and that this combination has promising antitumor activity. The purpose of this study was therefore to evaluate the antitumor activity of weekly bolus 5-FU + LV + AZT, administered at its MTD, and to determine whether 5-FU enhances AZT-induced DNA strand breaks in blood nuclear cells.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0923-7534
|
|
pubmed:author |
pubmed-author:AllegriniGG,
pubmed-author:AndreuccettiMM,
pubmed-author:AntonuzzoAA,
pubmed-author:BrunetteMM,
pubmed-author:DanesiRR,
pubmed-author:Del TaccaMM,
pubmed-author:FalconeAA,
pubmed-author:LencioniMM,
pubmed-author:MalvaldiGG,
pubmed-author:PfannerEE,
pubmed-author:YonemitsuHH
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
8
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
539-45
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:9261522-Adult,
pubmed-meshheading:9261522-Aged,
pubmed-meshheading:9261522-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:9261522-Colorectal Neoplasms,
pubmed-meshheading:9261522-DNA, Neoplasm,
pubmed-meshheading:9261522-DNA, Single-Stranded,
pubmed-meshheading:9261522-DNA Damage,
pubmed-meshheading:9261522-Dose-Response Relationship, Drug,
pubmed-meshheading:9261522-Drug Administration Schedule,
pubmed-meshheading:9261522-Female,
pubmed-meshheading:9261522-Fluorouracil,
pubmed-meshheading:9261522-Humans,
pubmed-meshheading:9261522-Injections, Intravenous,
pubmed-meshheading:9261522-Leucovorin,
pubmed-meshheading:9261522-Leukocytes, Mononuclear,
pubmed-meshheading:9261522-Male,
pubmed-meshheading:9261522-Middle Aged,
pubmed-meshheading:9261522-Neoplasm Metastasis,
pubmed-meshheading:9261522-Zidovudine
|
|
pubmed:year |
1997
|
|
pubmed:articleTitle |
Maximum tolerable doses of intravenous zidovudine in combination with 5-fluorouracil and leucovorin in metastatic colorectal cancer patients. Clinical evidence of significant antitumor activity and enhancement of zidovudine-induced DNA single strand breaks in peripheral nuclear blood cells.
|
|
pubmed:affiliation |
U.O. Oncologia Medica, Ospedale S. Chiara, Pisa, Italy.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
